Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | PPARG | P37231 | 11/20 | 0.65 |
| ▸ | FABP2 | P12104 | 1/20 | 0.59 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.59 |
| ▸ | PPARD | Q03181 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036305 | 0.94 | PPARA (0.62) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL4033102 | 0.94 | PPARA (0.62) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL1305108 | 0.87 | PPARA (0.54) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL11545612 | 0.85 | PPARA (0.71) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL1305105 | 0.84 | PPARA (0.51) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL3844599 | 0.83 | PPARA (0.69) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL4653170 | 0.83 | PPARA (0.69) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL16580097 | 0.83 | LMNA (0.52) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL16743652 | 0.83 | NPC1 (0.64) | PPARAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL247466 | 0.83 | PPARA (0.68) | PPARAMEN1KMT2ACYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132450-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARMACEUTICALS INC. | 2024-04-25 | — | — | US | disclosed |
| EP-3470407-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4263492-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA Pharmaceuticals Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230024108-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | TEON THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
| CN-114945572-A | HBF pharmacological inducing compounds for the treatment of sickle cell anemia and beta-thalassemia | 刘扶东 | 2022-08-26 | — | — | CN | disclosed |
| WO-2022129933-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | Pandeia Therapeutics Limited (GB) | 2022-06-23 | — | — | WO | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10953007-B2 | Compounds useful as modulators of TRPM8 | FIRMENICH INCORPORATED (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2021011670-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1796657-A2 | N-2 ADAMANTANYL-2-PHENOXY-ACETAMIDE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-20 | — | — | EP | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20060281773-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006074244-A2 | ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006024627-A2 | N-2 ADAMANTANYL-2-PHENOXY-ACETAMIDE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-09 | — | — | WO | disclosed |
| CN-1471517-A | OXAZOLYL-arylpropionic acid derivatives and their sue as PPAR agonists | — | 2004-01-28 | — | — | CN | disclosed |
| US-4039683-A | PHENOXYPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-08-02 | — | — | US | disclosed |
| US-3968143-A | Phenoxypropionic acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953007-B2 | Compounds useful as modulators of TRPM8 | TRPM8, TRPM7, TRPM6 | PPARA 2095/4885MEN1 476/4885KMT2A 2300/4885 |
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | PPARA 3756/4885MEN1 993/4885KMT2A 318/4885 |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | PPARA 871/4885MEN1 4864/4885KMT2A 2541/4885 |
| US-20230024108-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA3 | PPARA 754/4885MEN1 4350/4885KMT2A 2575/4885 |
| US-20240132450-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | GPR88, GPR65, GPR68 | PPARA 355/4885MEN1 4737/4885KMT2A 1498/4885 |
| US-20060281773-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | PPARA 1952/4885MEN1 1832/4885KMT2A 2594/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885MEN1 3749/4885KMT2A 4842/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885MEN1 3749/4885KMT2A 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.